The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma.

ABSTRACT:

Background

Standard of practice involves using transarterial therapy for multifocal hepatocellular carcinoma (HCC) alone and sorafenib only for more advanced HCC, but the sorafenib and transarterial therapy combination may provide greater efficacy.

Aim

To evaluate the safety and efficacy of concurrent sorafenib and transarterial therapy in HCC.

Methods

Consecutive cases of HCC were treated with sorafenib and transarterial therapy, receiving sorafenib 2 to 4weeks before transarterial therapy. Baseline clinical parameters, adverse events (AEs) and survival were collected.

Results

A total of 47 patients received sorafenib and transarterial therapy. The majority of the patients were male (70%) with HCV (60%), median age of 60years, good performance status (0-1), st

SUBMITTER: Cabrera R 

PROVIDER: S-EPMC3807574 | biostudies-literature | 2011 Jul

REPOSITORIES: biostudies-literature